Navigation Links
Predicting success

Chemotherapy drugs, given intravenously, are the mainstay of the fight against cancer. But doctors know that sometimes these drugs effect a complete cure, while other times they can be nearly ineffective. How to turn some of those failures into successes? A team of scientists at the Weizmann Institute, headed by Prof. Hadassa Degani of the Biological Regulation Department, has come up with a non-invasive, magnetic resonance imaging- (MRI-) based method for predicting possible problems. The findings of their studies on animals, which appeared in the journal Cancer Research, may, in the future, influence treatment regimes for millions of cancer patients.

Intravenous infusions rely on the bloodstream to carry drugs to where they are needed. Normally, a material such as a chemotherapy drug crosses into a tissue on the principle of concentration equalization ?the material diffuses from an area of high concentration to one of low concentration until the concentrations become equal all around. However, in some cancers, even though the material "wants" to spread out evenly, fluids inside the tumor may be exerting pressure to prevent this. When the internal pressure created by these fluids rises above a certain level, it acts as a barrier that keeps drugs and other materials from entering the tumor.

The method the Institute scientists developed can measure, with a non-invasive MRI scan, whether the fluid pressure in cancer tissues is at levels that could render chemotherapy ineffective. Their research, which led to the method, was done with MRI equipment similar to that found in hospitals and clinics. A contrast agent often employed in MRI was used as a stand-in for chemotherapy drugs, and this material was injected into special mice with different cancerous growths. The team created computer algorithms (instructions for computers) that allowed them to verify the connection between the amount of material that found its way into the growth and the pressure o
'"/>

Source:American Committee for the Weizmann Institute of Science


Page: 1 2

Related biology news :

1. Predicting chemotherapy outcome
2. Predicting successful outcomes in living-donor liver transplants
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Predicting success

(Date:4/17/2014)... one per eight hundred births, Down syndrome - or ... of intellectual disability. It results from a chromosomal abnormality ... of chromosome 21 (1% of the human genome). A ... the Department of Genetic Medicine and Development at the ... Nature , shed light on how the extra ...
(Date:4/17/2014)... House honored Clemson professor Rajendra Singh Thursday as ... promote and expand solar deployment in the residential, ... Houser Banks Professor of Electrical and Computer Engineering ... is considered a local hero leading the charge ... opportunity in solar power and driving policy changes ...
(Date:4/17/2014)... are implicated in many serious conditions such as heart ... target for drug therapies. Unfortunately, there is still much ... research provides fresh and unexpected insight into the structure ... - β-subunit molecules - which are responsible for ,fine-tuning, ... in the most recent edition of the Journal ...
Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3White House honors Clemson professor as 'Champion of Change' for solar deployment 2Structure of sodium channels different than previously believed 2
... Researchers at Northwestern University have developed a new ... providing an alternative that is more flexible and ... describing the results, "Low-Pressure Foaming: A Novel Method ... Engineering," was featured in the February issue of ...
... and Shenzhen, China BGI, the world,s largest ... Research Center located in Copenhagen Bio Science Park ... meters and equipped with 10 Illumina HiSeq 2000 ... better accelerate the innovation and development of genomics ...
... ON., Feb. 10, 2012--St. Michael,s Hospital and King Saud University ... BRCA1 gene as a therapy for cardiovascular disease. Dr. ... Mohammed Al-Omran, a vascular surgeon at the largest university in ... 110,185 B2 issued Feb. 7. Obtaining the patent is ...
Cached Biology News:Researchers develop new method for creating tissue engineering scaffolds 2BGI opens genome research center in Europe 2BGI opens genome research center in Europe 3
(Date:1/14/2014)... 2014 The largest international professional organization of ... therapeutic derivatives thereof has endorsed an educational program ... the challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural ...
(Date:1/14/2014)... 2014 iLab Solutions, the leader in core ... Director of Product Strategy. In this role, Michelle will work ... to guide in the development of iLab products. Her main ... possible benefit to the scientific community by offering the most ...
(Date:1/14/2014)...  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company ... addressing major unmet medical needs using RNA-targeted technologies, ... Allowance from the United States Patent and Trademark ... for the treatment of fibrosis. The patent covers ...
(Date:1/14/2014)... Ontario , Jan. 14, 2014   Kinaxis ®, provider ... SCM ) and sales and operations planning ( S&OP ) ... Biomanufacturing Summit , which will be held at the ... the conference, join Kinaxis customer Elisabeth Kaszas , Director ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... March 25 Trubion Pharmaceuticals, Inc. (Nasdaq: ... Pharmaceuticals, a division of Wyeth (NYSE: WYE ... SBI-087, Trubion,s next generation CD20 drug candidate, for the ... Small Modular ImmunoPharmaceutical (SMIP(TM)) technology, SBI-087 is also being ...
... PHILADELPHIA, March 25 In an economic environment ... Prime Health Network and its patients are thriving ... industry leading healthcare payments network and platform, Prime ... their costs related to collections, while also improving ...
... a privately held biotechnology company focused on developing novel ... sindbis viral vector, today announced that Frank Stonebanks, President ... National Venture Conference in Boston on Wednesday, April 1, ... LLC , Cynvec, a privately held biotechnology company, ...
Cached Biology Technology:Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE) 2Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE) 3Prime Health Network and Its Patients Thrive in Tough Economic Times on the InstaMed Network 2Prime Health Network and Its Patients Thrive in Tough Economic Times on the InstaMed Network 3
...
... with Annexin V-FITC to distinguish cells that ... (Annexin V positive, PI negative) from those ... or already dead (Annexin V-FITC positive, PI ... range of the spectrum using a 562-588 ...
... RPMI 1640 with 2 mM L-glutamine and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
... is a software package that provides ... for custom buffer creation, set-up of ... crystallization trials. The software helps crystallographers ... automated protein crystallography: ...
Biology Products: